Silence Therapeutics plc (Nasdaq: SLN)

https://www.silence-therapeutics.com

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including reduced cytokine induction and decreased manufacturing costs. Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets. The Company's lead internal drug candidate is Atu027, a liposomal AtuRNAi formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutics in the area of oncology. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as, repeated intravenous administration. The study is expected to be completed in the second half of 2011. The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer, and Quark. Silence is actively pursuing the establishment of additional partnerships. *

	Start	2007-04-26 renamed
	Group	Silence Therapeutics (Group)
	Predecessor	SR Pharma plc (AIM: SPA.L)
	Industry	siRNA therapeutic
	Person	Tooman, Craig A. (Silence Therapeutics 202202– CEO joined 1/21 before Vyome Tx + Aratana Tx + Avanzar Medical + Enzon)
	Person 2	Hellums, Rhonda (Silence Therapeutics 202202– CFO joined 4/21 before KCI + Genzyme + Deer Oaks Mental Health + Aratana)

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	72 Hammersmith Road
	City	W14 8TH London
	Tel	+44-20-3457-6900
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2022-12-31)
	Currency	GBP
	Annual sales	17,501,000 (revenue, consolidated (2022) 2022-12-31)
	Profit	-40,489,000 (2022-12-31)
	Cash	54,816,000 (2022-12-31)

		* Document for »About Section«:

		Record changed: 2024-02-13